Loading…
Precision oncology company making liquid-biopsy blood tests for cancer screening, treatment selection and recurrence monitoring.
Precision oncology company making liquid-biopsy blood tests for cancer screening, treatment selection and recurrence monitoring.
Is paid per test: Medicare, insurers and patients pay for each blood sample analysed, while drug developers pay for tests used to select patients in trials. Guardant360, for advanced cancer, is the established earner; Shield, approved by the FDA in 2024 as a colorectal cancer screening test, is the newer line. The company is still loss-making.
Moat: narrow (data, IP / patents, scale). Large proprietary genomic/clinical dataset and a first-mover position in liquid biopsy testing.
Headquarters: Palo Alto, California, USA · Founded: 2012 · Employees: 2,506
Size Guardant Health (GH) is a United States Health Care company (Medical Specialties) with a market value of $20.2B, the 491st largest of 3,117 United States companies the cockpit tracks. Shares closed at $150.87 on 6 Nov 2026.
Performance Over six months the shares gained 57.6%, against +28.7% for the median peer and -1.1% for the United States market (cap-weighted) — 3rd highest of 21 in its peer set.
Growth Revenue grew 42.7% over the last twelve months (peer median +6.5%); the operating margin is -39.7% (peer median 17.4%).
Valuation It trades at 17.7× enterprise value to sales against a peer median of 6.0× (2nd most expensive of 21).
Capital Return on invested capital runs 100.9 points below its cost of capital (12.6% WACC).
Credit Guardant Health has 2 bonds outstanding ($1.09B).
Short interest Short interest is 8.7% of the free float (15 Oct 2026).
Next results Next results expected around 25 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $1.18B | $982M | $739M | $564M | $450M |
| Revenue growth | — | +33% | +31% | +25% | — |
| Gross profit | $769M | $633M | $449M | $337M | $292M |
| EBITDA | -$431M | -$397M | -$401M | -$520M | -$499M |
| Net income | -$453M | -$416M | -$436M | -$479M | -$655M |
| Free cash flow | -$229M | -$233M | -$275M | -$345M | -$387M |
| Capital expenditure | $55.5M | $48.3M | $35.1M | $20.5M | $77.5M |
| Total debt | $1.70B | $1.71B | $1.34B | $1.35B | $1.37B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Guardant Health GH | $20.2B | +58% | +43% | -40% | 17.7× | n/a |
| Natera NTRA | $44.8B | +60% | +38% | -11% | 16.2× | n/a |
| GRAIL GRAL | $5.42B | +67% | +23% | -323% | 28.6× | n/a |
| Tempus AI TEM | $13.9B | +53% | +37% | -18% | 9.7× | n/a |
| Caris Life Sciences CAI | $7.13B | +56% | +85% | 15% | 6.9× | 18.7% |
| Personalis PSNL | $1.71B | +164% | -13% | -164% | 22.1× | n/a |
| Adaptive Biotechnologies ADPT | $4.47B | +103% | +50% | -12% | 14.7× | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | GH | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -8.9% | +11.3% | 2nd lowest of 21 |
| 6-month return | +57.6% | +28.7% | 3rd highest of 21 |
| Distance from 52-week high | -21.0% | -10.8% | 3rd lowest of 21 |
| Revenue growth (TTM) | +42.7% | +6.5% | 2nd highest of 21 |
| Operating margin | -39.7% | 17.4% | lowest of 21 |
| EV / Sales | 17.7× | 6.0× | 2nd most expensive of 21 |
| ROIC minus cost of capital | -100.9 pp | +2.2 pp | lowest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Guardant Health GH | United States | $20.2B | +58% | +43% | -40% | 17.7× | n/a | n/a |
| Sonova SOON.SW | Switzerland | $20.3B | +62% | -7% | 21% | 4.9× | 7.1% | +6.7% |
| Zimmer Biomet ZBH | United States | $20.1B | +29% | +7% | 16% | 3.2× | -1.4% | +3.2% |
| Straumann STMN.SW | Switzerland | $20.4B | +25% | +2% | 21% | 6.4× | 15.2% | +12.8% |
| Sartorius SRT.DE | Germany | $20.0B | +34% | +4% | 18% | 6.2× | 24.9% | +8.7% |
| Coloplast A/S COLO-B.CO | Denmark | $17.7B | +26% | +4% | 25% | 4.8× | -1.8% | +8.3% |
| Terumo 4543.T | Japan | $23.4B | +25% | +14% | 17% | 3.2× | 8.7% | +13.0% |
| Revvity RVTY | United States | $17.3B | +54% | +5% | 15% | 6.6× | 27.3% | -5.5% |
| Steris STE | United States | $24.6B | +22% | +8% | 20% | 4.3× | 13.7% | +13.8% |
| Sartorius Stedim Biotech DIM.PA | France | $24.7B | +38% | +4% | 19% | 7.9× | 33.1% | +9.2% |
| Shanghai United Imaging Healthcare 688271.SS | China | $14.8B | +9% | +27% | 9% | 6.2× | n/a | n/a |
| West Pharmaceutical Services WST | United States | $27.9B | +23% | +13% | 23% | 8.2× | 25.2% | +7.5% |
| Dexcom DXCM | United States | $29.6B | +31% | +13% | 24% | 5.7× | 18.5% | +19.3% |
| Lenskart Solutions LENSKART.NS | India | $13.4B | +49% | +35% | 10% | 12.3× | 52.8% | +33.5% |
| Baxter International BAX | United States | $13.3B | +43% | +5% | 6% | 1.7× | 12.7% | -0.7% |
| Glaukos GKOS | United States | $13.3B | +68% | +47% | -9% | 18.9× | n/a | n/a |
| Smith & Nephew SN..L | United Kingdom | $13.1B | +5% | +2% | 17% | 2.6× | 11.1% | +5.6% |
| Illumina ILMN | United States | $32.2B | +50% | +6% | 21% | 7.3× | 27.1% | +6.0% |
| Penumbra PEN | United States | $12.6B | -1% | +17% | 12% | 7.8× | 30.1% | +20.2% |
| ResMed RMD | United States | $33.1B | +14% | +9% | 34% | 5.7× | 4.9% | +12.1% |
| bioMerieux BIM.PA | France | $12.4B | +29% | -3% | 15% | 2.7× | 8.9% | +5.5% |
Guardant Health has 2 bonds outstanding with $1.09B face value.